Literature DB >> 19358776

Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose.

Philip Grant1, Andrew Zolopa.   

Abstract

Treatment guidelines have recently become more definitive regarding the optimal timing for initiation of combination antiretroviral therapy (ART) in the setting of an acute AIDS-related opportunistic infection (OI). These recent changes reflect new data from a prospective, randomized study and several retrospective studies, all of which support earlier initiation of ART during an OI. These studies focus on OIs for which effective antimicrobial therapy exists. For AIDS-related conditions that lack effective antimicrobial therapy, there are few studies to help inform the optimal timing to initiate ART, but most clinicians initiate ART early, as little else can be offered to these patients. For patients with HIV admitted for non-AIDS-related conditions, there are few data that directly address the optimal timing for ART. Initiating ART in the hospitalized patient can be challenging and requires a well-coordinated multidisciplinary team with expertise in ART management.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19358776     DOI: 10.1007/s11904-009-0010-3

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  31 in total

1.  Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance.

Authors:  Edward M Gardner; Shweta Sharma; Grace Peng; Katherine Huppler Hullsiek; William J Burman; Rodger D Macarthur; Margaret Chesney; Edward E Telzak; Gerald Friedland; Sharon B Mannheimer
Journal:  AIDS       Date:  2008-01-02       Impact factor: 4.177

2.  Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.

Authors:  Heather J Ribaudo; Daniel R Kuritzkes; Christina M Lalama; Jeffrey T Schouten; Bruce R Schackman; Edward P Acosta; Roy M Gulick
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

3.  A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women.

Authors:  Andrea A Howard; Julia H Arnsten; Yungtai Lo; David Vlahov; Josiah D Rich; Paula Schuman; Valerie E Stone; Dawn K Smith; Ellie E Schoenbaum
Journal:  AIDS       Date:  2002-11-08       Impact factor: 4.177

4.  Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia.

Authors:  Alison Morris; Robert M Wachter; John Luce; Joan Turner; Laurence Huang
Journal:  AIDS       Date:  2003-01-03       Impact factor: 4.177

5.  Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

Authors:  Gillian L Dean; Simon G Edwards; Natalie J Ives; Gail Matthews; Emma F Fox; Lesley Navaratne; Martin Fisher; Graham P Taylor; Rob Miller; Chris B Taylor; Annemiek de Ruiter; Anton L Pozniak
Journal:  AIDS       Date:  2002-01-04       Impact factor: 4.177

6.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

7.  Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

Authors:  Scott M Hammer; Joseph J Eron; Peter Reiss; Robert T Schooley; Melanie A Thompson; Sharon Walmsley; Pedro Cahn; Margaret A Fischl; Jose M Gatell; Martin S Hirsch; Donna M Jacobsen; Julio S G Montaner; Douglas D Richman; Patrick G Yeni; Paul A Volberding
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

8.  Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005.

Authors:  Kate Buchacz; Rose K Baker; Anne C Moorman; James T Richardson; Kathleen C Wood; Scott D Holmberg; John T Brooks
Journal:  AIDS       Date:  2008-07-11       Impact factor: 4.177

9.  Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

Authors:  A Mocroft; S Vella; T L Benfield; A Chiesi; V Miller; P Gargalianos; A d'Arminio Monforte; I Yust; J N Bruun; A N Phillips; J D Lundgren
Journal:  Lancet       Date:  1998-11-28       Impact factor: 79.321

10.  CD4+ count-guided interruption of antiretroviral treatment.

Authors:  W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

View more
  3 in total

1.  Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS.

Authors:  A Plettenberg; N H Brockmeyer; B Haastert; C Michalik; S Dupke; K Schewe; M Rausch; M Hower; A Ulmer; E Wolf; T Lorenzen; G Arendt; K Jansen
Journal:  Infection       Date:  2011-01-11       Impact factor: 3.553

2.  Superior Effects of Antiretroviral Treatment among Men Who have Sex with Men Compared to Other HIV At-Risk Populations in a Large Cohort Study in Hunan, China.

Authors:  Shu Su; Xi Chen; Limin Mao; Jianmei He; Xiuqing Wei; Jun Jing; Lei Zhang
Journal:  Int J Environ Res Public Health       Date:  2016-03-08       Impact factor: 3.390

Review 3.  Treatment of cryptococcal meningitis in resource limited settings.

Authors:  Derek J Sloan; Martin J Dedicoat; David G Lalloo
Journal:  Curr Opin Infect Dis       Date:  2009-10       Impact factor: 4.915

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.